Jefferies Financial Group Inc. Acquires 1,128,195 Shares of Revolution Medicines, Inc. $RVMD

Key Points

• Jefferies Financial Group sharply boosted its stake in Revolution Medicines, increasing holdings by 8,678.4% in the fourth quarter to 1,141,195 shares worth about $90.9 million.
• Institutional ownership remains very high, with several large investors also adding shares, including UBS Group, Nextech Invest, and Vanguard; institutions now own 94.34% of the stock.
• Revolution Medicines reported a wider-than-expected loss in its latest quarterly results, posting EPS of -$2.29 versus analyst expectations of -$1.83, even as analysts still generally rate the stock a Buy with a consensus price target of $111.35.

Jefferies Financial Group Inc. increased its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 8,678.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,141,195 shares of the company's stock after acquiring an additional 1,128,195 shares during the period. Revolution Medicines comprises approximately 0.5% of Jefferies Financial Group Inc.'s portfolio, making the stock its 20th biggest holding. Jefferies Financial Group Inc. owned about 0.59% of Revolution Medicines worth $90,896,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of RVMD. General Atlantic L.P. bought a new position in shares of Revolution Medicines in the third quarter valued at approximately $115,556,000. UBS Group AG grew its holdings in Revolution Medicines by 183.6% during the fourth quarter. UBS Group AG now owns 3,087,937 shares of the company's stock valued at $245,954,000 after purchasing an additional 1,998,972 shares during the period. Nextech Invest Ltd. grew its holdings in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the period. Vestal Point Capital LP bought a new position in Revolution Medicines during the second quarter valued at $44,148,000. Finally, Vanguard Group Inc. grew its holdings in Revolution Medicines by 6.7% during the fourth quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company's stock valued at $1,331,739,000 after purchasing an additional 1,056,792 shares during the period. 94.34% of the stock is owned by institutional investors.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $151.56 on Friday. Revolution Medicines, Inc. has a one year low of $34.00 and a one year high of $156.25. The business has a fifty day moving average price of $123.75 and a 200-day moving average price of $101.21. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The firm has a market capitalization of $32.22 billion, a P/E ratio of -21.44 and a beta of 1.41.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing analysts' consensus estimates of ($1.83) by ($0.46). During the same period in the previous year, the company earned ($1.13) earnings per share. As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -7.75 EPS for the current year.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 2,753 shares of the firm's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the completion of the transaction, the chief financial officer directly owned 125,512 shares of the company's stock, valued at $12,485,933.76. This trade represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark A. Goldsmith sold 120,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the sale, the insider owned 276,698 shares in the company, valued at $41,529,602.82. This trade represents a 30.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 184,592 shares of company stock valued at $24,499,532. 8.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on RVMD. Piper Sandler increased their price objective on Revolution Medicines to $172.00 and gave the company an "overweight" rating in a report on Thursday, May 7th. Evercore reissued an "outperform" rating on shares of Revolution Medicines in a report on Tuesday, April 14th. UBS Group began coverage on Revolution Medicines in a report on Friday, February 27th. They set a "buy" rating for the company. Royal Bank Of Canada increased their price objective on Revolution Medicines to $165.00 and gave the company an "outperform" rating in a report on Thursday, May 7th. Finally, HC Wainwright reissued a "buy" rating on shares of Revolution Medicines in a report on Wednesday, April 22nd. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $111.35.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.